BMO Capital Reiterates Outperform Rating on Biogen (BIIB)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
Leqembi® (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain
August 22, 2024 5:11 AM UTCFOR GLOBAL MEDIA AND JOURNALISTS OUTSIDE THE EMEA REGIONÂ
In Great Britain, lecanemab is indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease (AD) in adult patients that are apolipoprotein E 4 (ApoE 4)* heterozygotes or non-carriers1
Great Britain becomes the first country in Europe to authorize the medicine, which targets an underlying cause of... More
